The Pharmaceutical Journal Vol 267 No 7172 p633-638
3 November 2001

This article
Reprint
Photocopy

News summary

Additional data for using alefacept to treat psoriasis

Patients with chronic plaque psoriasis who experience a reduction in symptoms after treatment with alefacept, a recombinant protein, remain in remission for a median duration of seven months, new data show.

These patients received intravenous alefacept once a week for 12 weeks and maintained a 50 per cent or greater reduction in their base-line symptom scores.

The phase III trial data were presented at the 10th annual congress of the European Academy of Dermatology and Venereology in Munich and follow on from research published in The New England Journal of Medicine (see PJ, 4 August, p145).

Back to Top